

EQA round: T23/23 - Antibodies IgG anti EM and anti tTG (study)

Deadline: 23.10.2023

Setup: Slovakia

AV = assigned value

N_{tot} = total number of the resultsN_{eva} = number of the results assessed

CVP = consensus of all participants

N_{rel} = relative number of the resultsN_{suc} = number of successful results

>>> ... expected result

S_{rel} = relative success

> ... acceptable result

± ... result not assessed

| Test Sample Group | Frequency of the results | | | | Success | | |
|--|--------------------------|------------------|-------------------------|----------------------------------|------------------|------------------|-------------------------|
| | AV | N _{tot} | N _{rel} [%] | Result | N _{eva} | N _{suc} | S _{rel} [%] |
| (437) anti-endomysium IgG | | 9 | | | 9 | 7 | 78 |
| Sample A | | 9 | | | 9 | 9 | 100 |
| All results | CVP >>> | 9 | 100 | Negative | | | |
| Sample B | | 9 | | | 9 | 7 | 78 |
| All results | | 1 | 11 | Negative | | | |
| | | 1 | 11 | Inconclusive result (borderline) | | | |
| | CVP >>> | 7 | 78 | Positive | | | |
| (438) anti-transglutaminase IgG | | 17 | | | 17 | 16 | 94 |
| Sample A | | 17 | | | 17 | 16 | 94 |
| All results | CVP >>> | 16 | 94 | Negative | | | |
| | | 1 | 5,9 | Positive | | | |
| Sample B | | 17 | | | 17 | 16 | 94 |
| All results | | 1 | 5,9 | Negative | | | |
| | CVP >>> | 16 | 94 | Positive | | | |